Adicet Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies, announced participation in three virtual investor conferences in August 2021. Key highlights include a fireside chat by CEO Chen Schor at the BTIG Virtual Biotechnology Conference on August 9 at 9:00 AM ET and a panel discussion on August 10 during the Wedbush PacGrow Healthcare Conference, as well as another fireside chat on August 11 at the Canaccord Genuity Annual Growth Conference. A webcast will be available on their investor website.

MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in three upcoming virtual investor conferences in August.

Details of the events are as follows:

The BTIG Virtual Biotechnology Conference 2021, August 9-10, 2021
Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Monday, August 9, 2021 at 9:00 AM ET

Wedbush PacGrow Healthcare Conference 2021, August 10-11, 2021
Chen Schor, President and Chief Executive Officer, will participate in a panel discussion on Tuesday, August 10, 2021 at 9:45 AM ET

Canaccord Genuity 41st Annual Growth Conference, August 10-12, 2021
Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on Wednesday, August 11, 2021 at 8:00 AM ET

A live audio webcast of the Canaccord Genuity fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

FAQ

When will Adicet Bio participate in the BTIG Virtual Biotechnology Conference?

Adicet Bio will participate in the BTIG Virtual Biotechnology Conference on August 9-10, 2021, with CEO Chen Schor's fireside chat scheduled for August 9 at 9:00 AM ET.

What is the schedule for Adicet Bio's participation in investor conferences?

Adicet Bio will participate in the Wedbush PacGrow Healthcare Conference on August 10-11, 2021, and the Canaccord Genuity Annual Growth Conference on August 10-12, 2021.

Where can I access the live audio webcast of Adicet Bio's presentations?

The live audio webcast of Adicet Bio's presentations can be accessed on the Investors section of their website.

What is the focus of Adicet Bio's research and development?

Adicet Bio focuses on discovering and developing allogeneic gamma delta T cell therapies targeting cancer and other diseases.

Who is the CEO of Adicet Bio, and what will he discuss at the conferences?

Chen Schor is the CEO of Adicet Bio. He will discuss the company's advancements in gamma delta T cell therapies during the conferences.